Product image of Granisetron Fresenius Kabi (Granisetron Hydrochloride) supplied by GNH India

Granisetron Fresenius Kabi

Active Ingredient:
Granisetron Hydrochloride
Origin:
EU

Granisetron Fresenius Kabi (Granisetron Hydrochloride)

Granisetron Fresenius Kabi, containing the active ingredient granisetron hydrochloride, is an injectable intravenous formulation marketed in the European Union. It belongs to the 5‑HT3 receptor antagonist class and is prescribed as an antiemetic to help prevent nausea and vomiting associated with chemotherapy and postoperative recovery. The product is available by prescription and is not a controlled substance. It is supplied as a solution for intravenous infusion and is stored refrigerated.

Manufacturer / TM Owner

Fresenius Kabi Nederland B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Granisetron Fresenius Kabi is indicated for the prevention of nausea and vomiting in specific clinical settings.

  • Prevention of chemotherapy‑induced nausea and vomiting (CINV).
  • Prevention of postoperative nausea and vomiting (PONV).
  • May be used as part of a prophylactic antiemetic regimen for patients receiving highly emetogenic chemotherapy.
  • Can be administered before surgical procedures to reduce the risk of postoperative emesis.
  • May be combined with other antiemetic agents such as dexamethasone for enhanced efficacy.

Side Effects

The safety profile of Granisetron Fresenius Kabi includes both common and less frequent adverse reactions.

Common

  • Headache.
  • Constipation.
  • Dizziness or light‑headedness.
  • Fatigue or weakness.
  • Diarrhea.
  • Mild injection‑site discomfort or erythema.

Serious

  • Allergic reactions including anaphylaxis, rash, or angioedema.
  • QT interval prolongation on electrocardiogram.
  • Cardiac arrhythmias, especially in patients with pre‑existing heart conditions.
  • Severe hypotension.
  • Serotonin syndrome, particularly when combined with serotonergic drugs.
  • Significant hepatic dysfunction or liver enzyme elevations.

Precautions & Warnings

Clinicians should consider several precautions when prescribing Granisetron Fresenius Kabi.

  • Use with caution in patients with known cardiac conduction abnormalities or a history of prolonged QT interval.
  • Assess hepatic and renal function, as impairment may affect drug clearance.
  • Pregnancy category is unknown; avoid use unless the potential benefit justifies the risk.
  • Monitor for signs of hypersensitivity during and after infusion.
  • Avoid concurrent use of other QT‑prolonging agents when possible.
  • Adjust dosing in elderly patients if clinically indicated.

Avoid Interactions

Granisetron Fresenius Kabi can interact with other medications, requiring attention to avoid adverse effects.

Avoid

  • Concomitant use with other 5‑HT3 antagonists (e.g., ondansetron) due to additive effects.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that may increase granisetron plasma levels.
  • Drugs known to prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics).

Use with caution

  • Other antiemetics such as metoclopramide or dexamethasone.
  • Anesthetic agents that may affect cardiac conduction.
  • Serotonergic agents (e.g., SSRIs) in patients at risk for serotonin syndrome.

Frequently Asked Questions

Granisetron Fresenius Kabi is a prescription‑only intravenous formulation of granisetron hydrochloride, classified as a 5‑HT3 receptor antagonist used to prevent nausea and vomiting.

Granisetron selectively blocks serotonin 5‑HT3 receptors in the central nervous system and gastrointestinal tract, interrupting the signaling pathway that triggers emesis.

It is commonly prescribed for patients undergoing chemotherapy or those undergoing surgery who are at risk for postoperative nausea and vomiting.

The pregnancy safety category is unknown, so it should only be used if the potential benefit outweighs any possible risk to the fetus.

Common side effects include headache, constipation, dizziness, fatigue, diarrhea, and mild discomfort at the injection site.

Serious reactions can include allergic responses such as anaphylaxis, QT interval prolongation, cardiac arrhythmias, severe hypotension, serotonin syndrome, and significant liver enzyme changes.

Concurrent use with other 5‑HT3 antagonists should be avoided, while other antiemetics may be used with caution under medical supervision.

Drugs known to prolong QT, such as certain antiarrhythmics (e.g., amiodarone), antipsychotics (e.g., haloperidol), and some antibiotics, should be avoided or closely monitored.

It is administered by intravenous infusion, typically under the supervision of a healthcare professional in a clinical setting.

The product should be stored refrigerated (2‑8 °C) and protected from light to maintain stability.

Dose adjustments may be considered for patients with significant hepatic or renal dysfunction, and clinicians should evaluate individual patient factors.

When combined with serotonergic agents such as SSRIs, there is a theoretical risk of serotonin syndrome, so use with caution.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Granisetron Hydrochloride

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT